Target intelligence / Profile preview

Hemoglobin subunit gamma-1 promoter genomic DNA sequence (HBG1 promoter)

Target
HBG1 promoter
Molecular classification
Genomic DNA, Gene promoter, Non-coding DNA, Other
01

Overview

The Hemoglobin subunit gamma-1 (HBG1) promoter genomic DNA sequence is a critical regulatory region located on chromosome 11 that controls the transcription of the A-gamma globin gene, a key component of fetal hemoglobin (HbF, alpha2gamma2). During fetal development, the HBG1 promoter is active, but it is epigenetically silenced shortly after birth by transcriptional repressors such as BCL11A and ZBTB7A, facilitating the transition to adult hemoglobin (HbA, alpha2beta2). In patients with beta-hemoglobinopathies like sickle cell disease (SCD) and beta-thalassemia, adult hemoglobin is either mutated or deficient, leading to severe clinical complications. Reactivating the expression of fetal hemoglobin by targeting the HBG1 promoter has emerged as a highly promising therapeutic strategy, as elevated HbF levels can functionally compensate for defective adult hemoglobin and prevent red blood cell sickling.\n\nTherapeutic approaches targeting the HBG1 promoter utilize advanced gene-editing technologies, including CRISPR-Cas9, CRISPR-Cas12a, and base editors, to introduce precise modifications. These edits typically disrupt the binding sites of transcriptional repressors (such as BCL11A) or recreate naturally occurring mutations associated with hereditary persistence of fetal hemoglobin (HPFH), a benign condition that maintains high HbF levels into adulthood. Investigational therapies like ristoglogene autogetemcel (BEAM-101) and EDIT-301 target this promoter ex vivo in patient-derived hematopoietic stem and progenitor cells (HSPCs), which are subsequently reinfused to establish a durable, long-term source of healthy, HbF-producing red blood cells.

Other names
HBG1 promoterGamma-1 globin promoterAgamma-globin promoterA-gamma globin promoterHemoglobin subunit gamma-1 promoterHBG1 promoter genomic DNA sequence
02

Mechanism of action

Disruption of the BCL11A transcriptional repressor binding site or recapitulation of hereditary persistence of fetal hemoglobin (HPFH) mutations via gene editing (CRISPR-Cas9, CRISPR-Cas12a, or base editing) to reactivate fetal hemoglobin (HbF) expression.

03

Biological functions

Gene expression regulationTranscription regulationHemoglobin synthesisOther
04

Disease associations

Sickle cell diseaseBeta-thalassemiaHemoglobinopathyOther
05

Safety considerations

Off-target genomic editing (genotoxicity)Chromosomal rearrangements or translocationsMyeloablative conditioning-related toxicities (e.g., from busulfan)Incomplete or transient engraftment of edited hematopoietic stem cellsClonal hematopoiesis or insertional mutagenesis
06

Interacting drugs

Ristoglogene autogetemcel (BEAM-101)

2 more in the full profile.

07

Biomarkers

Fetal hemoglobin (HbF) levelsF-cell percentageTotal hemoglobin levelsHemolysis markers (e.g., lactate dehydrogenase, bilirubin)On-target editing efficiency (indel frequency or base conversion rate)

Beyond the preview

Go deeper on Hemoglobin subunit gamma-1 promoter genomic DNA sequence (HBG1 promoter).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin subunit gamma-1 promoter genomic DNA sequence (HBG1 promoter).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call